TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25338776

Group type: EXPERIMENTAL
Intervention: Imipramine or venlafaxine (antidepressants)
Number of subjects: 149
Study: 24518937

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally 2 hours before surgery and 12.5 mg of heavy bupivacaine 0.5% intrathecally
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intrathecal fentanyl 10 μg plus 12.5 mg of heavy bupivacaine 0.5%
Number of subjects: 78
Study: 22028408

Group type: EXPERIMENTAL
Intervention: 72-h fast
Number of subjects: 8

Group type: COMPARATOR
Intervention: 10-h overnight fast
Number of subjects: 8
Study: 19717886

Group type: EXPERIMENTAL
Intervention: 3D image-based planning
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 4DCT image-based planning
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tracking regimen
Number of subjects: 6

Group type: COMPARATOR
Intervention: Static conventional and gated radiotherapy
Number of subjects: 6
Study: 17519078

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Alutard SQ (ASQ)
Number of subjects: 0
Study: 15132762

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12166543

Group type: EXPERIMENTAL
Intervention: Somatostatin (SS)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Octreotide (OC)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Pitressin plus Nitroglycerine (PN)
Number of subjects: 224
Study: 9734620

Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine microemulsion)
Number of subjects: 167
Study: 8208176

Group type: EXPERIMENTAL
Intervention: General practice obstetric clinics (n = 18)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hospital obstetric clinics (n = 24)
Number of subjects: 42
Study: 2722269

Group type: EXPERIMENTAL
Intervention: Nursing home staff training in care for the dying
Number of subjects: 306

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 306
Study: 4920799

Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Riboflavine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31994278

Group type: EXPERIMENTAL
Intervention: Nutraceutical compound containing Ilex paraguariensis, White Mulberry and Chromium Picolinate (500 mg), taken once a day for 3 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, taken once a day for 3 months.
Number of subjects: 0
Study: 29063490

Group type: EXPERIMENTAL
Intervention: Somatosensory training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 27911621

Group type: EXPERIMENTAL
Intervention: Exergaming for Health intervention group (exergaming and classroom curriculum)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (classroom curriculum alone)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Exergaming for Health intervention group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 24393610

Group type: EXPERIMENTAL
Intervention: EMMS supplementation and schooling ≥6 years
Number of subjects: 3625

Group type: EXPERIMENTAL
Intervention: EMMS supplementation and schooling <6 years
Number of subjects: 3625

Group type: COMPARATOR
Intervention: Standard program and schooling ≥6 years
Number of subjects: 3625
Study: 22980375

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic measures
Number of subjects: 15
Study: 19933412

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (GTN; 0.6 mg/h) for 2 hours on 1 day only
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transdermal GTN for 2 hours/day for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous therapy with transdermal GTN for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of vitamin C after continuous GTN therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 24
Study: 19791552

Group type: EXPERIMENTAL
Intervention: Femoropopliteal bypass grafting supplemented by gene stimulators of angiogenesis (gene constructions with the genes of vascular endothelial growth factor, and angiogenin)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reconstructive vascular operation alone
Number of subjects: 38
Study: 15939567

Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Number of subjects: 193

Group type: COMPARATOR
Intervention: Delayed-treatment control condition
Number of subjects: 193
Study: 14636809

Group type: EXPERIMENTAL
Intervention: Pathways intervention
Number of subjects: 470
Study: 12903463

Group type: EXPERIMENTAL
Intervention: Gossypol (15 mg/d for 12 weeks, then 10 mg/d for 32 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study: 9333168

Group type: COMPARATOR
Intervention: Hepatitis A vaccine (2 mL of 720 ELISA units/mL) given to HIV-infected men either 1 or 6 months apart; HIV-uninfected men received vaccine at study entry and at 6 months.
Number of subjects: 134
Study: 8448264

Group type: EXPERIMENTAL
Intervention: 25 g of glucose
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Blood glucose levels
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Insulin response
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Blood tryptophan levels
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tryptophan/LNAA ratio
Number of subjects: 41
Study: 3096634

Group type: EXPERIMENTAL
Intervention: Levonorgestrel and Ethinyl Estradiol as an oral tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Levonorgestrel and Ethinyl Estradiol as a solution
Number of subjects: 24
Study: 3407613

Group type: EXPERIMENTAL
Intervention: Intrinsically labeled beef (100 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Extrinsically labeled beef (100 g)
Number of subjects: 12
Study: 30777447

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 0
Study: 28526377

Group type: EXPERIMENTAL
Intervention: OJ group (500 mL/d of 100% orange juice)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (RCD without OJ)
Number of subjects: 78
Study: 26194655

Group type: EXPERIMENTAL
Intervention: 8-week brisk walking program (Experimental Group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 86
Study: 24334780

Group type: EXPERIMENTAL
Intervention: Treatment with an additional escalating reinforcement scheme (n = 72)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Treatment as usual (n = 64)
Number of subjects: 136
Study: 21546203

Group type: EXPERIMENTAL
Intervention: Experimental group (socio-cognitive intervention with pedometer)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 19182698

Group type: EXPERIMENTAL
Intervention: 10 g/day of MF101
Number of subjects: 217

Group type: COMPARATOR
Intervention: 5 g/day of MF101
Number of subjects: 217
Study: 16813739

Group type: EXPERIMENTAL
Intervention: Intensive management of diabetes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contemporary coronary revascularization (angioplasty)
Number of subjects: 0
Study: 12453926

Group type: EXPERIMENTAL
Intervention: Codeine 1.5 mg kg(‐1)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Morphine 0.15 mg kg(‐1)
Number of subjects: 96
Study: 10892897

Group type: EXPERIMENTAL
Intervention: Cerazette (75 microg desogestrel)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Liseta (150 microg desogestrel and 1.5 mg 17beta‐estradiol)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous dose of 150 microg etonogestrel
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cerazette (multiple dosing, 1 tablet once daily for 7 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cerazette (single-dose treatments)
Number of subjects: 24
Study: 7734230

Group type: EXPERIMENTAL
Intervention: Rearthroplasty group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (non-reoperated patients)
Number of subjects: 12
Study: 1828158

Group type: EXPERIMENTAL
Intervention: Calcium supplementation during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0
Study: 7269326

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements analysis
Number of subjects: 0
Study: 30648358

Group type: EXPERIMENTAL
Intervention: EGb 761® (Ginkgo biloba extract)
Number of subjects: 0
Study: 28768538

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anterior neurectomy
Number of subjects: 0
Study: 26003313

Group type: EXPERIMENTAL
Intervention: Benefit Finding Scale (BFS-C) at T1
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Worldview, family relationship, social relationship, and acceptance at T1
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Personal growth, worldview, family relationship, and acceptance at T1
Number of subjects: 658
Study: 23394825

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy Eating (HE) education control group
Number of subjects: 22
Study: 21138606

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol-enriched sunflower oil (HSO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-enriched sunflower oil (Control)
Number of subjects: 22
Study: 18483232

Group type: EXPERIMENTAL
Intervention: Iso-osmolality iodixanol (n = 61)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Low-osmolality iopromide (n = 56)
Number of subjects: 117
Study: 16943537

Group type: COMPARATOR
Intervention: Melphalan alone
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Melphalan plus TNF-alpha
Number of subjects: 133
Study: 14502085

Group type: EXPERIMENTAL
Intervention: 2 mg haloperidol (dopaminergic D2 receptor antagonist)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11300369

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg for 12 months)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study: 8982289

Group type: EXPERIMENTAL
Intervention: rHuG‐CSF alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: conventional chemotherapy (C.CHE) + rHuG‐CSF
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: high dose cytoxan (HD.CTX) + rHuG‐CSF
Number of subjects: 18

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 18
Study: 1518513

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 11
Study: 6100597

Group type: EXPERIMENTAL
Intervention: MK-421
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study: 30575407

Group type: EXPERIMENTAL
Intervention: Amphetamine extended-release oral suspension (AMPH EROS) 15, 17.5, or 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29063518

Group type: EXPERIMENTAL
Intervention: ALZ-801 (265 mg twice daily)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: ALZ-801 with food
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Immediate-release tablet formulation of ALZ-801
Number of subjects: 127
Study: 26842771

Group type: EXPERIMENTAL
Intervention: 40 g freeze-dried whole strawberry powder (FDS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 20 g freeze-dried whole strawberry powder (FDS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10 g freeze-dried whole strawberry powder (FDS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0 g freeze-dried whole strawberry powder (FDS, control)
Number of subjects: 21
Study: 26695407

Group type: EXPERIMENTAL
Intervention: 5As Team intervention (5AsT); delivered in a series of 12 workshops; content based on 43 topics related to 13 themes around obesity assessment and management.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5As Team intervention (5AsT); included videos, resources, and tools.
Number of subjects: 0
Study: 23732992

Group type: EXPERIMENTAL
Intervention: Minimally invasive intervention (MII) involving aspirating iliac crest bone marrow and peripheral blood to yield mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP), mixed with demineralized bone matrix (DBM) and injected into the fracture site.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 24
Study: 20148270

Group type: EXPERIMENTAL
Intervention: ESAs alone
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Combination of ESAs and parenteral iron
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Iron only
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Normochromic patients treated with ESAs alone
Number of subjects: 286
Study: 17971261

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16896685

Group type: EXPERIMENTAL
Intervention: Higher-order wavefront analysis using discriminant analysis from PISD and Zernike coefficients
Number of subjects: 8

Group type: COMPARATOR
Intervention: Single Zernike coefficients
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Discriminant functions based on PISD and higher-order Zernike coefficients
Number of subjects: 8
Study: 14533837

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on day 1, followed by 250 mg once a day on days 2 to 5)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Cefadroxil (500 mg twice a day for 10 days)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 296

Group type: COMPARATOR
Intervention: Cefadroxil
Number of subjects: 296
Study: 10779658

Group type: EXPERIMENTAL
Intervention: Capsaicin injection (50 microg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Controlled-force stimuli (16, 32, and 64 g) applied via a 12-mm wide, 100-microm thick blade probe
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hand-held 20-g von Frey probe
Number of subjects: 9
Study: 9235663

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 62
Study: 1529745

Group type: EXPERIMENTAL
Intervention: des‐enkephalin‐gamma‐endorphin (DE‐gamma‐E) 10 mg given as a once daily intramuscular injection for 4 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: thioridazine 400 mg orally in 2 divided doses
Number of subjects: 96

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: thioridazine
Number of subjects: 96
Study: 2856778

Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide + triamterene)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 840
Study: 30059989

Group type: EXPERIMENTAL
Intervention: Interleukin-27 (IL-27) plasma levels
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Microarray results confirmed by quantitative PCR and ELISA
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cancer pathway gene expression data
Number of subjects: 153
Study: 30227092

Group type: EXPERIMENTAL
Intervention: Etched with hydrofluoric (HF) acid
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Etched with Er:YAG laser at 250mJ, 20Hz
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Etched with Er:YAG laser at 300mJ, 20Hz
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Etched with Er:YAG laser at 250mJ, 20Hz combined with HF etching
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Etched with Er:YAG laser at 300mJ, 20Hz combined with HF etching
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90
Study: 26995375

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 1970
Study: 24414607

Group type: EXPERIMENTAL
Intervention: Vitamin D 1,000 IU/day and elemental calcium 500 mg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium co-administration
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 41
Study: 22369408

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Non-tibolone (NT-group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (premenoausal women)
Number of subjects: 83
Study: 19752398

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 5804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 5804
Study: 18506735

Group type: EXPERIMENTAL
Intervention: Norfloxacin formulation 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norfloxacin formulation 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciprofloxacin (used as internal standard)
Number of subjects: 0
Study: 15947511

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour group therapy (CBGT), 12 two-hour sessions over 6 months
Number of subjects: 67

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 67
Study: 12853808

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 or 2 x 0.4 mg daily)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 609
Study: 10601507

Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided antiarrhythmic therapy (including drugs and implantable defibrillators)
Number of subjects: 704

Group type: COMPARATOR
Intervention: No antiarrhythmic therapy
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Defibrillator treatment
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided therapy with antiarrhythmic drugs
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 704
Study: 8109766

Group type: EXPERIMENTAL
Intervention: High-volume (HV) group: bupivacaine 0.125% with sufentanil 0.7 microgram/mL, 6-8 mL/h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-volume (LV) group: bupivacaine 0.75% with sufentanil 4 micrograms/mL, 1.0-1.3 mL/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 3262973

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20034162

Group type: EXPERIMENTAL
Intervention: Sodium amobarbital
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hydroxydione
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Methamphetamine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 49
Study: 29703024

Group type: EXPERIMENTAL
Intervention: JianPi HuaZhuo XingNao formula (JPHZXN)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 28615261

Group type: EXPERIMENTAL
Intervention: 10 μg/d vitamin D3 supplementation
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 25 μg/d vitamin D3 supplementation
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 6 μg/d vitamin D intake
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 14 μg/d vitamin D intake
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 20 μg/d vitamin D intake
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 28 μg/d vitamin D intake
Number of subjects: 206

Group type: COMPARATOR
Intervention: 2 μg/d placebo
Number of subjects: 206
Study: 24629419

Group type: EXPERIMENTAL
Intervention: Prescribed position changes during colonoscope withdrawal
Number of subjects: 776

Group type: COMPARATOR
Intervention: Usual care per endoscopist
Number of subjects: 776
Study: 22436144

Group type: EXPERIMENTAL
Intervention: Helical Tomotherapy (HT) with a dose of 60 Gy/10 fractions
Number of subjects: 93

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Helical Tomotherapy (HT)
Number of subjects: 93
Study: 20421834

Group type: EXPERIMENTAL
Intervention: Aquatitan garments
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo garments
Number of subjects: 14
Study: 18797657

Group type: EXPERIMENTAL
Intervention: 2% ibopamine provocative test
Number of subjects: 25

Group type: COMPARATOR
Intervention: Water drinking test
Number of subjects: 25
Study: 15781547

Group type: EXPERIMENTAL
Intervention: Sevoflurane-propofol (8% sevoflurane + 1.5 mg/kg IV propofol)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sevoflurane alone (8%)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Propofol alone (3 mg/kg IV)
Number of subjects: 83
Study: 14685951

Group type: EXPERIMENTAL
Intervention: Short education program about the disorder and lithium therapy (3 sessions)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no education program)
Number of subjects: 26
Study: 10378490

Group type: EXPERIMENTAL
Intervention: Low-intensity laser therapy (1.06 microm neodymium:yttrium-aluminum-garnet laser, 542mW/cm2)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (inactive laser probes)
Number of subjects: 63
Study: 8749965

Group type: EXPERIMENTAL
Intervention: Lighted stylet
Number of subjects: 73

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 73
Study: 1430280

Group type: EXPERIMENTAL
Intervention: Oral health education (OHE) programme with systematic brushing practice
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no OHE programme)
Number of subjects: 62
Study: 3155992

Group type: EXPERIMENTAL
Intervention: Nocardia rubra cell wall skeleton (N-CWS) treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (chemotherapy)
Number of subjects: 119
Study: 30980127

Group type: EXPERIMENTAL
Intervention: Multi-energy texture analysis
Number of subjects: 87

Group type: COMPARATOR
Intervention: Single-energy (65 keV) texture evaluation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Iodine material decomposition maps
Number of subjects: 87
Study: 29298800

Group type: EXPERIMENTAL
Intervention: 0.2 mg/day pemafibrate
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 0.4 mg/day pemafibrate
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166